Adare Collaborate with Laxxon to Add 3D Printing from Milan Facility
Adare, the global technology-driven oral dose CDMO, will mark CPHI with the announcement that it has partnered with Laxxon Medical to provide GMP 3D oral dose printing from Adare’s Pessano facility in Milan.
Adare and Laxxon will utilize Exentis Group’s Screen-Printed Innovative Drug (SPID®) Technology to create 3D-printed oral dosage forms featuring advanced geometric internal structures and a heterogeneous distribution of active ingredients, allowing for formulation of complex pharmaceuticals with customized release profiles of one or more APIs, improved bioavailability, and tailored pharmacokinetics.
The 3D printing system will be fully operational by end of Q4 2024, and a second clinical-scale 3D production system is planned for installation at Adare’s Vandalia, Ohio, facility at the end of 2024.
Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced a collaboration with Laxxon Medical, a pharma-technology company pioneering a new generation of advanced pharmaceuticals, to provide the pharmaceutical market with cGMP 3D printing capabilities from Adare’s Pessano facility in Milan, Italy.
Adare and Laxxon will utilize the Screen-Printed Innovative Drug (SPID®) Technology, licensed from Exentis Group, to create 3D-printed oral dosage forms featuring advanced geometric internal structures and a heterogeneous distribution of active ingredients. This will allow for formulation of complex pharmaceuticals with optimized properties, including freely customizable release profiles of one or more APIs, improved bioavailability, and tailored pharmacokinetics. The platform enables production of multi-compartment tablets ranging from as small as 200 microns up to centimeters in diameter, as well as a direct upscale from lab- to mass-production without changing the production process.
A 3D printing system and a new bulk preparation mixer have been installed at the Pessano site and will be fully operational by end of Q4 2024. This flexible cGMP suite will permit direct scaling from Laxxon’s laboratory quantities through to clinical trial material volumes.
Tom Sellig, CEO of Adare Pharma Solutions said, “Our Pessano facility provides comprehensive CDMO solutions to customers in Europe, the United States, and Asia. Adare’s collaboration with Laxxon expands our ability to provide incredible dose flexibility options such as taste masking, solubility enhancement, shape modifications for ease of swallowing, and multiple APIs.”
“Laxxon’s partnership with Adare represents a significant step forward in actualizing our mission to drive disruptive global drug delivery and manufacturing solutions,”
Helmut Kerschbaumer, CEO of Laxxon Medical, said. “This is an essential collaboration for Laxxon; Adare, with their CDMO expertise and state-of-the-art cGMP facilities, will enable us to produce clinical samples for our partners as well as our own internal pipeline.”
The proprietary SPID® Technology was developed and is being provided by Exentis Group, Switzerland, which has granted Laxxon the worldwide exclusive license for using its 3D technology platform for pharmaceutical applications.
Adare’s 220,000 square foot (20,400 square meter) Pessano facility provides R&D service capabilities for expedited formulation and process development, with a seamless integrated transition to manufacturing. The site can produce a wide range of solid dosage forms at both clinical and commercial scales, including granules, capsules, and tablets. The facility is presently undergoing additional expansion to add upgraded high potency, packaging, and warehousing capabilities.
A second clinical-scale 3D production system is planned for installation at Adare’s Vandalia, Ohio facility at the end of Q4 2024. The addition of clinical-scale machines at facilities in Europe and North America will give Adare and Laxxon proximity to the two largest pharmaceutical markets for this innovative technology.
For more, please find the original story source here.
